Skip to main content

Table 4 Functions of parameter estimates for different fractional polynomials

From: Network meta-analysis of survival data with fractional polynomials

  Fixed effects model, first order fractional polynomial Fixed effects model, second order fractional polynomial Random effects model (d0), second order fractional polynomial
  Median of posterior distribution 95% Credible Interval Median of posterior distribution 95% Credible Interval Median of posterior distribution 95% Credible Interval
Docetaxel *       
   β0A -2.422 (-2.502; -2.348) -2.689 (-2.882; -2.476) -2.694 (-2.895; -2.513)
   β1A -2.174 (-2.988; -1.401) -1.224 (-2.324; -0.198) -1.193 (-2.267; -0.206)
   β2A    0.013 (0.004; 0.022) 0.014 (0.006; 0.022)
Gefitinib       
   β0B0A +d 0AB ) -2.425 (-2.515; -2.325) -2.531 (-2.776; -2.322) -2.550 (-2.777; -2.273)
   β1B1A +d 1AB ) -1.540 (-2.527; -0.631) -1.227 (-2.407; 0.082) -1.124 (-2.433; 0.010)
   β2B2A +d 2AB )    0.007 (-0.002; 0.018) 0.008 (-0.002; 0.016)
BSC       
   β 0C0A +d 0AC ) -1.652 (-1.818; -1.461) -1.015 (-1.600; -0.480) -1.041 (-1.554; -0.462)
   β1C1A +d 1AC ) -4.681 (-6.564; -3.010) -7.082 (-9.677; -4.320) -7.032 (-9.700; -4.622)
   β2C2A +d 2AC )    -0.040 (-0.071; -0.008) -0.039 (-0.069; -0.010)
Pemetrexed       
   β0D0 A +d 0AD ) -2.402 (-2.616; -2.188) -2.548 (-3.101; -1.954) -2.552 (-3.093; -1.978)
   β1D1A +d 1AD ) -3.169 (-5.445; -0.673) -2.583 (-5.634; 0.308) -2.561 (-5.329; 0.167)
   β2D2A +d 2AD )    0.009 (-0.018; 0.033) 0.009 (-0.014; 0.028)
Expected survival (in months)       
   docetaxel 12.5 (11.9; 13.3) 13.0 (12.2; 13.8) 13.0 (12.2; 13.9)
   gefitinib 12.1 (11.3; 13.0) 12.2 (11.3; 13.2) 12.2 (10.6; 14.0)
   BSC 7.2 (6.5; 8.1) 6.2 (5.1; 7.6) 6.2 (4.8; 7.9)
   pemetrexed 12.7 (10.9; 14.7) 12.7 (10.5; 15.0) 12.9 (9.5; 17.4)
Difference in expected survival (in months)       
   gefitinib vs docetaxel -0.4 (-1.4; 0.6) -0.8 (-1.9; 0.3) -0.8 (-2.6; 1.1)
   BSC vs docetaxel -5.3 (-6.2; -4.3) -6.8 (-8.0; -5.4) -6.8 (-8.4; -5.0)
   pemetrexed vs docetaxel 0.1 (-1.8; 2.2) -0.3 (-2.5; 2.0) -0.2 (-3.6; 4.4)
   BSC vs gefitinib -4.9 (-6.0; -3.8) -6.0 (-7.4; -4.5) -6.0 (-8.1; -3.9)
   pemetrexed vs gefitinib 0.5 (-1.6; 2.8) 0.4 (-2.0; 3.0) 0.6 (-3.2; 5.3)
   pemetrexed vs. BSC 5.4 (3.4; 7.6) 6.4 (3.9; 9.1) 6.7 (3.0; 11.4)
  1. * (calculated as average from docetaxel study specific estimates: μ0, μ1, μ2)